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Abstract
Purpose: The incidental detection of one or more additional primary tumours during computed tomography (CT) 
staging of a patient with known malignancy is rare but possible. This occurrence should be considered by the radi-
ologist when a new lesion is detected, especially if the lesion location is atypical for metastases. The purpose of this 
report was to document the usefulness of total body CT scan to detect synchronous primary malignancies in cancer 
patients undergoing a staging workup. 
Material and methods: This was done by reviewing the staging CT studies of the adult patients with a newly diagnosed 
cancer evaluated during a five-year period in a single cancer institute in order to identify any possible correlation, 
establishing which tumours are more frequently combined with a second tumour and which second tumours are 
more commonly present. 
Results: Among the patients with a second tumour, the most frequent first primary tumours were melanoma (eight 
patients, 17.8%), lymphoma (seven patients, 15.6%), and prostate carcinoma (seven patients, 15.6%). The most 
frequent incidentally detected second tumours were hepatocellular carcinoma (nine patients, 20% of 45 incidental 
tumours), renal carcinoma (eight patients, 17.8%), lung carcinoma (seven patients, 15.6%), and bladder carcinoma 
(four patients, 8.9%). One patient had three primary tumours synchronously. 
Conclusions: We believe that the radiologist’s knowledge of the prevalence and pattern of occurrence of these multiple 
primary malignancies represents added diagnostic value.
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Introduction
Multiple primary malignancies (MPMs), defined as two 
or more malignant primary tumours arising in the same 
patient, are an uncommon but well recognised medical 
evidence, especially for clinicians and oncologists [1,2]. 
MPMs present the following clinical and histological 
characteristics: (1) malignant tumours based on histo-
pathologic criteria, (2) topographic distinction without 
connection (skip lesions), and (3) ruling out that the sec-
ond tumour is not a metastasis of the first. This avoids 
misclassification of multifocal or multicentric tumours or 
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metastases as multiple primaries. A cancer is classified as 
index cancer if there has been no prior record of invasive 
cancer. In addition, a temporal classification describes 
MPMs as synchronous or metachronous, depending on 
whether diagnosis of the second tumour was made within 
or after six months of the first (“index tumour”) [1,2].
When a new cancer diagnosis occurs, staging examina-
tions are performed to assess the extent of disease [3]. In 
this clinical scenario, it is not uncommon for the radiologist 
who is performing a computed tomography (CT) study to 
find suspicious lesions, which are often superficially classi-
fied as metastases but instead could be MPMs [4,5].
In particular, discovery of another incidental primary 
malignancy changes significantly the patient management. 
For example, in some cases the second primary tumour 
may require treatment more urgently than the first ma-
lignancy, for which therapy would then be deferred [5,6].
Thus, radiologists should be able to detect the multiple 
primary tumours revealed by CT, and should not auto-
matically consider any additional CT finding as due to 
a metastasis, especially for those lesions located outside 
the frequent sites of tumour metastasis [7,8].
Aim of our retrospective, single-cancer-centre study 
was to assess the incidence of second, occult primary tu-
mours in a large population undergoing staging CT, and 
to determine the type and extent of these tumours. This 
was done to identify any possible correlation, establish-
ing which tumours are more frequently combined with 
a second tumour, and which second tumours are more 
commonly present. 
We believe that the radiologist’s knowledge of the 
prevalence and pattern of occurrence of MPMs represents 
added diagnostic value.
Material and methods
We reviewed the clinical charts of adult patients with 
a newly diagnosed cancer evaluated from January 1, 2014 
to December 31, 2019 in a single cancer institute of the 
metropolitan area of Naples, Southern Italy. 
According to Warren and Gate’s criteria [9], a second 
tumour was defined as a previously unknown malignancy 
of a different histological type detected in the same organ 
of the first primary cancer or in another organ. All of the 
primary tumours in MPMs patients occurring simultane-
ously or within six months were classified as synchronous. 
Inclusion criteria were: availability of good-quality 
staging CT studies and availability of a definitive diagnosis 
for all tumours present in the same patient. Patients with 
central nervous system (CNS) tumours were not included 
in our study, having been assessed in the Neuroradiology 
Unit by other colleagues. Also, only patients older than 
18 years were included because young subjects are not ad-
mitted to our institution. 
The enrolled patients harboured MPMs in different 
systems, including digestive tumours, neck cancers, lung 
cancers, urinary tumours, reproductive tumours, breast 
tumours, haematological malignancies, and endocrine tu-
mours. The pathological types and clinical stages of ma-
lignancies were stratified separately according to the 3rd 
Edition of the International Classification of Diseases for 
Oncology (ICD-O) [9] and the 7th Edition of the Ameri-
can Joint Committee on Cancer (AJCC) [10].
CT was used to investigate all morphologic and dy-
namic features of neck, chest, abdomen, and pelvis pri-
mary tumours and their patterns of local, nodal, and hae-
matogenous tumour spread. The identification of nodal 
involvement on CT was based on nodal size, typically 
using a minimum cut-off of 1 cm in short-axis diameter, 
although this approach may have led to both under- and 
over-staging of metastatic nodal involvement.
The standard of reference for confirming the pres-
ence or absence of malignancy was either histopathol-
ogy (biopsy or surgery) or clinical-radiological follow-up 
for at least six months, based on Response Criteria In 
Solid Tumours (RECIST) [11]. Tumour progression in 
the follow-up CT scan or decrease in lesion size during 
ongoing systemic therapy were considered positive for 
the presence of malignancy. Lack of change or decrease 
in size of a lesion without ongoing systemic therapy over 
at least a six-month interval was considered negative for 
malignancy. 
CT scanning of the neck, chest, abdomen, and pel-
vis was performed using a 64-slice multidetector CT 
(MDCT) scanner (LightSpeed VCT, GE Healthcare). All 
patients received a bolus injection (2.5 cc/s) of non-ionic 
iodinated contrast media (Iopamiro 370 mgI/ml Bracco 
Imaging, Milan, Italy) followed by 200 cc of saline solu-
tion with a dual-head injector (Stellant Injection System, 
Medrad Inc., United States). The administered amount 
of CT contrast agents was adjusted according to age and 
weight. CT scanning was done using three volumes, with 
the first volume including the chest, abdomen, and pelvis 
in the unenhanced phase, the second volume including 
the neck and chest in the arterial phase, and the third 
volume including the chest, abdomen, and pelvis in the 
portal venous phase. Specifically, arterial and portal ve-
nous acquisitions were performed with fix scan delays of 
35 and 80 s after intravenous bolus injection of iodinated 
contrast media.
Technical scan parameters were the following: detector 
configuration = 1 × 32 mm; table feed 36 mm/s; rotation 
time = 0.75 s; helical pitch = 27; section thickness = 5 mm; 
120 kVp; automated tube current modulation. From the 
raw data of the acquisition, 3 mm thick transverse sec-
tions were reconstructed with 1.5 mm increments. Tube 
voltage and tube setting were 120 kV and 130 mAs for 
the neck and chest region and 120 kV and 200 mAs for 
the abdominal and pelvic region with application of au-
tomatic tube current modulation. The computed tomog-
raphy dose index volume (CTDIvol) ranged between 3.0 
and 5.0 mGy. 
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Categorical variables are presented as the number 
of patients and percentages. Fisher’s exact test was used 
for statistical comparisons of the two groups (with and 
without second tumour). It was used also to calculate the 
relative risk for each risk factor considered, including pa-
tient age, sex, and ethnic correlation. P-values less than 
0.05 were considered statistically significant. All statisti-
cal analyses were performed using MedCalc for Microsoft 
Windows (version 13.1.2.0, MedCalc).
Results
Overall, 1247 subjects (18-88 years old, mean 50.1 years) 
were enrolled. These included 653 males (52.4%) and 594 
females (47.6%). There were 1202 patients without CT 
evidence of a second tumour (prevalence 96.4%, includ-
ing 625 males and 577 females – mean age 50.6 years) 
and 45 patients with CT detection of a second tumour 
(prevalence 3.6%, including 28 males and 17 females – 
mean age 64.1 years) (Table 1). Among MPM patients, the 
relative risk increased with patient age and male sex, while 
no ethnic correlation was found. 
The second tumour could be classified as non-ad-
vanced in 16/45 cases (35.6%) and as advanced in 29/45 
cases (64.4%). In one case only the second tumour was 
in the same organ as the first one (hepatocellular carci-
noma [HCC] plus cholangiocellular carcinoma). In all 
the remaining cases, the second tumour was in a different 
organ. 
Among the patients with a second tumour, the most 
frequent first primary tumours were melanoma (eight 
patients, 17.8%) (Figure 1), lymphoma (seven patients, 
15.6%) (Figures 2 and 3), and prostate carcinoma (seven 
patients, 15.6%) (Table 2 and Figure 4). 
The most frequent incidentally detected second tu-
mours were hepatocellular carcinoma (nine patients, 
20% of 45 incidental tumours) (Figure 5), renal carcinoma 
(eight patients, 17.8%) (Figure 6), lung carcinoma (seven 
patients, 15.6%) (Figure 7), and bladder carcinoma (four 
patients, 8.9%) (Figure 8). One patient had three primary 
tumours synchronously. The distribution of second tu-
mours according to tumour type is shown in the histo-
gram in Figure 9. In two patients, a synchronous occur-
rence of primary tumours in which one of them showed 
a multifocal growth pattern was found. Specifically, the 
multifocal tumours were one HCC (Figure 1) and one 
bladder carcinoma (Figure 10). 
Discussion
The first report about MPMs was in 1889 by Billroth, 
which described a patient with a spinocellular epithelioma 
of the right ear and a gastric carcinoma [12]. Until 1932, 
when Warren and Gates classified 1259 such patients 
from literature reports and post-mortem examinations, 
only a few such cases had been recognised [13]. Since that 
time, numerous series and case reports in the literature 
have cited similar occurrences involving a single organ or 
multiple organ systems [1,2]. 
In recent years, the incidence of MPMs is increasing 
and is expected to continue to do so. This increase has 
been ascribed to several factors, such as better imaging 
detection of many forms of cancer, longer mean lifetime, 
mostly in Western populations, treatments at initial tu-
mour staging, quality of oncologic follow-up, and better 
prognosis of many neoplasms [14-16]. According to the 
literature, 1.2-3.5% of cancer patients are unexpectedly 
affected by a new synchronous neoplasia detected during 
a diagnostic or therapeutic phase [17]. Overall, the risk of 










Mean age 61 years 74 years 62 years
Males 625 28 653
Females 577 17 594
Figure 1. Axial contrast-enhanced computed tomography (CT) scans. Inci-
dental detection of multifocal hepatocellular carcinoma (HCC) (A) (yellow 
arrows point to HCC nodules) in a 58-year-old female patient undergoing 
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Figure 2. Axial (A, B) and coronal (C) contrast-enhanced computed tomog-
raphy (CT) scans. Incidental detection of hepatocellular carcinoma (HCC) 
(A) (yellow arrow) in a 78-year-old male patient undergoing CT staging for 





Table 2. Distribution of primary tumour according to the tumour-type










Breast carcinoma 116 4 (8.9%) 120
Lung carcinoma 149 2 (4.4%) 151
Melanoma 111 8 (17.8%) 119
Hepatocellular carcinoma 137 1 (2.2%) 138
Pancreatic carcinoma 44 1 (2.2%) 45
Stomach carcinoma 88 1 (2.2%) 89
Colorectal carcinoma 108 4 (8.9%) 112
Soft-tissue sarcoma 74 2 (4.4%) 76
Ovarian carcinoma 68 2 (4.4%) 70
Uterine carcinoma 67 2 (4.4%) 69
Prostate carcinoma 81 7 (15.6%) 88
Lymphoma 83 7 (15.6%) 90
Other primary tumours 76 4 (8.9%) 80
Figure 3. Axial (A) and sagittal (B) contrast-enhanced computed tomogra-
phy (CT) scans. Incidental detection of cervix carcinoma (yellow arrow) in 
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developing a second primary malignancy varies in differ-
ent cancer sites and is reported to range from 1% (primary 
liver malignancy) to 16% (primary bladder cancer) [18].
To date, there is no universal diagnostic technique 
with overall oncologic accuracy, neither are there di-
agnostic guidelines to detect synchronous MPMs [6]. 
The choice between CT, magnetic resonance imaging 
(MRI), positron emission tomography (PET), and even 
ultrasound (US) depends on the tumour type or body re-
gion [19,20].
The most widespread and recommended method for 
cancer staging is contrast-enhanced multidetector CT 
(MDCT) because it allows total-body evaluation within 
an extremely short time frame and, through volumetric 
acquisition, provides a multiplanar reconstruction of the 
tissues and organs of interest [21,22]. 
Both the primary tumour and associated tumours 
in adjacent and/or distant organs can be detected [23]. 
However, despite the interesting perspective that is 
achieved by high-quality multiplanar reconstruction 
MDCT imaging and its utility in the correct assessment 
of tumour extension, CT sensitivity in discovering fur-
ther tumours is relatively low (85-90%), especially in the 
case of lesions not distinguishable from benign abnor-
mality (e.g. cutaneous melanoma, small thyroid tumour, 
or prostate carcinoma) [24]. 
To maximise the efficiency of contrast-enhanced 
MDCT to be a real “one-stop-shop” oncology examination, 
a controversial issue refers to the optimal scanning proto-
col. The question is which protocol is needed to address as 
many specific diagnostic problems as possible. Currently 
there are no universal diagnostic CT protocols [25]. 
In order to better detect both metastatic disease and 
MPMs, administration of intravenous contrast material 
with a multiphasic approach is essential [25,26]. The rou-
tine use of intravenous media, unless contraindicated in 
some patients, helps to delineate sites of disease, espe-
cially within solid organs. In our institution, all patients 

















































































































Figure 5. Axial (A, B) and sagittal (C) contrast-enhanced computed tomog-
raphy (CT) scans. Incidental detection of hepatocellular carcinoma (A) (yel-
low arrow) in a 68-year-old male patient undergoing CT staging for right 
kidney clear-cell carcinoma (B) (dashed circle). C) Both tumours are shown 
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underwent a contrast-enhanced CT with a three-phase 
approach including unenhanced, arterial, and portal ve-
nous acquisition. Similarly, scanning volumes must be 
appropriate to ensure a “diagnostic CT” [25]. In patients 
with tumours of the neck-chest-abdomen-pelvis, we nor-
mally limited our total-body scan to an examination of 
Figure 6. Axial (A, B, E) and coronal (C, D) contrast-enhanced computed 
tomography (CT) scans. Incidental detection of renal clear-cell carcinoma 
(A) (yellow arrow) with nodal metastasis to the mediastinum (B) (green 
arrow) and renal vein thrombosis (D) (yellow arrow) and in a 65-year-old 
female patient undergoing CT staging for sigmoid colon adenocarcinoma 
(E) (red arrows). C) Both renal clear-cell carcinoma and nodal metastasis to 






the base of the skull, neck, chest, and abdomen down to 
the upper thighs. In patients with malignant melanoma 
or peripheral sarcoma, instead, the upper extremities and 
lower extremities were included in the scan, but at the 
cost of an increase in examination time and dose to the 
patient. 
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Figure 7. Sagittal contrast-enhanced computed tomography (CT) scan. In-
cidental detection of lung adenocarcinoma (yellow arrow) in a 47-year-old 
female patient undergoing CT staging for cheek cutaneous melanoma with 
cervical lymph node metastasis (red arrows)
Figure 8. Axial (A, B) and coronal (C) contrast-enhanced computed tomog-
raphy (CT) scans. Incidental detection of bladder carcinoma (A) (dashed 
circle) in a 76-year-old male patient undergoing CT staging for epidermoid 





Minimising the radiation dose delivered to patients 
while preserving the diagnostic accuracy of the CT ex-
amination should be a radiologist’s duty in the current 
era of MDCT technology [27]. Indeed, radiologists 
should always attempt to obtain a diagnostic benefit-to-
risk ratio as high as reasonably achievable (AHARA), and 
such a radiation consciousness should primarily involve 
patients under 30 years old because the lifetime risk of 
radiation-induced cancer is greater the younger the pa-
tient. Although several dose-reduction strategies can be 
successfully applied in contrast-enhanced MDCT, such 
as the use of iterative reconstruction algorithms com-
bined with either low tube voltage or low tube current 
protocols, these technologies are still not widely avail-
able in clinical practice. Thus, dose reduction in MDCT 
should primarily result from the optimisation of acquisi-
tion protocols, because unindicated acquisition phases or 
inappropriately wide scan volumes in contrast-enhanced 
MDCT are a major source of unjustified radiation expo-
sure [27,28].
Techniques that non-invasively yield in vivo informa-
tion on cellular metabolism, such as PET, can be used 
in cancer assessment to detect unexpected tumour sites 
based on the increased uptake of radioactive tracer [29]. 
In clinical practice, the most commonly used radiotracer 
is 18F-labelled fluorodeoxyglucose (FDG). Cancer lesions 
accumulate higher concentrations of radiotracer than 
normal tissue and are therefore recognisable as areas of 
increased radioactive intensity, which can be quantified 
and followed over time [30].
PET-CT scanners combine the morpho-functional 
images of PET with the anatomical images provided by 
CT. These devices offer the advantage of an accurate cor-
respondence between areas of physiological and patho-
logical radioactive tracer collection and anatomical land-
marks, an essential feature in the correct interpretation 
of PET images, and thus reduce the number of false posi-
tives. Overall, the reported sensitivity and specificity of 
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Figure 10. Axial (A, B) and coronal (C) contrast-enhanced computed to-
mography (CT) scans. Incidental detection of multifocal bladder carcino-
ma (A) (yellow arrows and dashed circle) in a 70-year-old male patient 
undergoing CT staging for lung adenocarcinoma (B) (red arrows). C) Both 













































































































































PET-CT in the detection of MPMs has been demonstrated 
to be, respectively, 91% and 69% [31-33]. 
Among intrinsic limitation of 18FDG-techniques, 
there is no qualitative distinction between inflammatory 
and neoplastic tissue, and it is often difficult to assess or-
gans that tend to concentrate large amounts of FDG (e.g. 
thyroid, liver, bladder). Also, several kinds of tumours are 
not FDG-amenable, such as renal cell carcinoma, pros-
tate cancer, and gastric lesions, particularly small ones, 
in which the tracer concentration is limited, such as early 
gastric cancer, deep liver lesions, and low-grade soft-tissue 
malignancies. In the absence of pronounced morphologi-
cal changes, this may lead to false-negatives in early-stage 
disease. Furthermore, the high cost of PET-CT, its limited 
availability restricted to a few specialised centres, and the 
guidelines limiting the amount of radiation allowed for 
each first-stage diagnostic session restrict its use [6].
For these reasons, baseline FDG-PET is not extensively 
performed in clinical practice, and the majority of these 
examinations were acquired after CT studies. Thus, CT 
remains the most commonly used imaging modality for 
staging newly diagnosed tumours, and in some cases it is 
the only imaging test needed prior to surgical management. 
This aspect further confirms the usefulness of our research.
Our study had some limitations. First, a selection bias. 
Although we used a population-based surveillance sys-
tem, we studied only data from a single hospital. In ad-
dition, the patients enrolled were selected from a popula-
tion of patients entering in our cancer institute, which is 
a regional reference centre in the diagnosis and treatment 
of melanomas and lymphomas. Therefore, it was obvious 
that melanoma and lymphoma patients had a high preva-
lence of MPMs. Second, only patients with newly diag-
nosed synchronous MPMs were included, and the results 
of this study may not apply to other, larger MPMs pa-
tient populations. Third, our retrospective study includes 
data for an observation period of only five years. In our 
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opinion, a more sophisticated analysis of MPMs requires 
a larger, well-defined population under observation for 
≥ 10 years. Fourth, patients with CNS tumours were not 
included in our study, having been assessed in the Neuro-
radiology Unit by other colleagues. Similarly, only patients 
older than 18 years were included in the study because 
young subjects are not admitted to our institution. And 
fifth, patients experience of staging CT was not compared 
to that of FDG-PET or FDG-PET/CT.
Conclusions
Our study deals with multiple primary tumours coex-
isting in the same organ or in different organs in the same 
patient and detected synchronously during CT staging. 
Because the clinical implications and therapeutic strate-
gies vary significantly according to a correct diagnosis, 
radiologists should be aware of this occurrence. 
Thus, when planning the CT acquisition, radiologists 
should evaluate all the possibilities of using a multiphasic 
CT approach in order to improve the diagnostic accuracy 
of the examination, but they should try to avoid unin-
dicated acquisition phases or inappropriately wide scan 
volumes as a source of unjustified radiation exposure.
Additionally, when reviewing the CT images, they 
should not automatically consider any new lesion as a me-
tastasis. Particularly in the case of an uncommon site of 
metastatic lesion, a second primary tumour should be 
considered in the differential diagnosis.
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